SEO Press Releases North Hollywood, CA, September 22, 2010 — According to an article posted on Sept. 3 in Infectious Disease News data was presented at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy showing the quadrivalent human papillomavirus vaccine (Gardasil) did not raise the risk for developing autoimmune conditions. The study was sponsored […]
MILFORD, Conn., Sep 20, 2010 (BUSINESS WIRE) — S.A.N.E. Vax, Inc. and Dr. Sin Hang Lee, on behalf of Milford Medical Laboratory, have agreed to offer a reliable human papillomavirus (HPV) genotyping test using a PCR system with short target DNA sequencing for safe vaccination practice.
Recognizing the alleged flaw in the two FDA-approved HPV tests, the National Cancer Institute (NCI) has awarded a contract to a Dutch diagnostic laboratory to perform “reliable genotyping using a PCR system with short target sequences” for the HPV isolated from biopsy samples collected in the NCI.
S.A.N.E. Vax, Inc. is a non-profit organization founded to promote safe, affordable, necessary and effective vaccines and vaccination practices. Dr. Lee said, “Milford Medical Laboratory will perform nested PCR with short target DNA sequencing for HPV genotyping on liquid-based cytology samples referred by S.A.N.E. Vax, Inc. at $50 per sample. Most health insurance companies will reimburse this cost.”